serine peptidase inhibitor, Kunitz type 4Genealiases: C20orf137 · dJ601O1.1
Q-omics provides the consensus-scored SPINT4 profile across patient tissues and cancer cell-line models. SPINT4 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, SPINT4 is differentially expressed in 1, with the highest sampling consensus in LUAD. Additionally, SPINT4 RNA expression shows 10,178 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight LIHC, LUAD, and PDAC as cancer lineages where SPINT4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPINT4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPINT4 survival associations across molecular data types. SPINT4 RNA expression shows survival associations in the most cancer types (11), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPINT4 RNA expression–survival associations across cancer types. High SPINT4 expression shows unfavorable associations in LIHC, ACC, LUSC, KIRP and COAD, but favorable associations in MESO. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for SPINT4 RNA expression.
This table summarizes SPINT4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for SPINT4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPINT4 shows higher tumor expression in LUAD. The LUAD box plot shows higher SPINT4 RNA expression in tumor versus normal tissue (log2 FC = +0.302, t-test p = .015).
This table shows molecular features associated with SPINT4 in patient tissues and cancer cell lines. In patient samples, SPINT4 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, SPINT4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LUNG_NSCLC_LUSC.
